Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00560937 · ClinicalTrials.gov registry record · NA

Pilot Study of Pregnenolone Augmentation Targeting Cognitive Symptoms in Persistently Symptomatic Patients With Schizophrenia

A NA study of Schizophrenia, sponsored by Durham VA Medical Center.

Completed
Registry status
NA
Development phase
28
Enrollment target
1
Study location

NCT00560937: Completed NA study of Schizophrenia, sponsored by Durham VA Medical Center.

NCT00560937 is a NA study of Schizophrenia that has completed, run by Durham VA Medical Center. The registered enrollment target is 28 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00560937, a NA study of Schizophrenia, has completed, sponsored by Durham VA Medical Center.

COMPLETED
Registry status
NA
Development phase
28 participants
Enrollment target
1
Study location

Study Summary

This is a pilot study of pregnenolone as an augmentation treatment for schizophrenia. The goal of this placebo-controlled study is to provide preliminary efficacy data for potential pregnenolone effects on cognitive symptoms and negative symptoms in patients with schizophrenia. Depressive symptoms and positive symptoms will also be assessed.

Primary Outcome

The SANS assesses negative symptoms in schizophrenia. The SANS consists of 21 clinical interview questions assessing negative symptoms of schizophrenia. Each question is rated on a scale of 0 (no symptoms) to 7 (severe symptoms).

Conditions Studied

Schizophrenia

Interventions

  • DRUG Placebo
  • DRUG Pregnenolone

Study Locations (1)

North Carolina

  • Durham VAMC - Durham

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2005-06
Est. Completion 2008-04
Phase NA
Durham VA Medical Center

17 total trials

What the finished NCT00560937 record still lists

NCT00560937 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (87% lower).

The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00560937 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT00560937 about?

NCT00560937 is a clinical study titled "Pilot Study of Pregnenolone Augmentation Targeting Cognitive Symptoms in Persistently Symptomatic Patients With Schizophrenia". This is a pilot study of pregnenolone as an augmentation treatment for schizophrenia. The goal of this placebo-controlled study is to provide preliminary efficacy data for potential pregnenolone effects on cognitive symptoms and negative symptoms in patients with schizophrenia. Depressive symptoms a...

What is the current status of trial NCT00560937?

This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2005-06. Estimated completion is 2008-04.

What conditions does trial NCT00560937 study?

This clinical trial studies the following conditions: Schizophrenia.

What interventions are being tested in trial NCT00560937?

The interventions under investigation include: Placebo (DRUG), Pregnenolone (DRUG).

Who is sponsoring clinical trial NCT00560937?

This trial is sponsored by Durham VA Medical Center, which has 17 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00560937 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00560937's enrollment target sits among peer trials

28 268th of 315 higher than 47 of 315 other Schizophrenia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03471117 · 28 participants · Phase 4

    Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

  • NCT03523975 · 28 participants · Phase 1

    Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

  • NCT03608631 · 28 participants · Phase 1

    iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

  • NCT03810651 · 28 participants · Early Phase 1

    Pencil Beam Scanning in Patients With Renal Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00560937, the US trial registry maintained by the National Library of Medicine. NCT00560937 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.